Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Travera Inc
Turning Point Therapeutics, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
Eli Lilly and Company
Sensei Biotherapeutics, Inc.
Tempus AI
Intensity Therapeutics, Inc.
Immunophotonics, Inc.
Taproot Health
pharmaand GmbH
Kineta Inc.
Aesculap AG
Genzada Pharmaceuticals USA, Inc.
MacroGenics
SpeciCare
MedInnovation GmbH
Altor BioScience
INSYS Therapeutics Inc